Day: February 24, 2026

New virtual agent capabilities reduce customer effort, prevent repeat contacts, and give service leaders confidence to scale automation With 43% of consumers saying chatbots fail to resolve their issues, Zoom Virtual Agent 3.0 can help organizations close that gapSAN JOSE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Today Zoom Communications, Inc. (NASDAQ: ZM) unveiled Zoom Virtual Agent 3.0 (ZVA), the next evolution in agentic automation. ZVA introduces a new execution architecture and expanded AI capabilities designed to resolve customer issues end to end, seamlessly hand off to human agents, and help enterprises shift from transactional service interactions to connected customer relationships. Organizations face growing pressure to automate more customer service interactions as volumes rise and cost efficiency becomes a priority....

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced its award-winning photographers, editors and operations staff will capture stunning imagery from the Milano Cortina 2026 Paralympic Winter Games. As the Official Photographic Agency of the International Paralympic Committee (IPC), Getty Images will deploy a team of 30 photographers, editors and operations staff to capture live coverage of all six Paralympic winter sports at five Winter Paralympic competition venues spread across three regions, using innovative and proprietary technology to deliver over 25,000 images from the Opening Ceremony on March 6 to the Closing Ceremony on March 15. “We recognize...

Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technology NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deployment of INBS’s fingerprint drug screening technology across its UK operations. The partnership reflects a shift from third-party testing services to an in-house solution, driven by superior hygiene protocols, operational efficiency, and demonstrated...

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9:20 a.m. ET. The webcast of Mr. Schmitt’s presentation will be available at: https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/guest_book?session_id=ZnLyeyXAyDLdm9UCBhJPaT The Actuate management team is scheduled to host one-on-one meetings with investors and attendees during the conference. Registered attendees can...

Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) First and only direct telomere-targeting anticancer agent in clinical development anywhere MAIA CEO details development pipeline in letter to shareholders CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in clinical trials of its lead molecule, ateganosine, as a treatment for non-small cell...

Holds of Over 9,000 ETH-based Cryptocurrencies and Staked 2,600 ETH as of February 23, 2026 SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we” or the “Company”), a company engaged in the provision of altcoin mining products, and delivery of Web3 infrastructure services via the strategic acquisition and holding of Ethereum-based cryptocurrencies, and operation of a Proof-of-Stake (“PoS”) cryptocurrency staking platform, today provided an update on its Ethereum (“ETH”) accumulation and staking activities. Accelerating ETH Accumulation and Staking StrategyIntchains’ ETH treasury strategy follows a disciplined dollar-cost averaging (DCA) approach, allocating capital at regular intervals to steadily accumulate ETH over time. The Company believes this approach mitigates the impact of short-term ETH...

SOUTHLAKE, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) — Renewal Fuels, Inc. (OTC: RNWF) (“RNWF”, “American Fusion” or the “Company”), together with Kepler Fusion Technologies Inc. (“Kepler”), today announced the availability of a new follow-up interview with Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies and Dr. John E. Brandenburg, Ph.D., Chief Technology Officer for Kepler. The discussion expands on Nelson’s earlier remarks regarding the Company’s proprietary radiation-free fusion platform, Texatron™, and provides deeper insight into engineering progress, commercialization pathways, and the Company’s targeted 2026 deployment timeline. Link to the full interview: https://youtu.be/bkqxP9UljlwAdvancing Toward a 100-Megawatt Operational Unit In the interview, Nelson reaffirms Kepler’s goal of delivering a...

Initial pilot to tokenize up to $10 million of ResMac-originated mortgage loans; platform launch expected within 45 to 60 days pending pilot completion IRVINE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — via IBN — ECGI Holdings, Inc. (OTC:ECGI) today announced it has signed a platform services agreement with Nomyx Technology Labs Inc., a tokenization infrastructure provider. The agreement activates the core tokenization stack supporting the RezyFi mortgage tokenization platform and begins pilot testing. The pilot will test the tokenization of up to $10 million in mortgage loans originated by ResMac, a wholly owned subsidiary of RezyFi. ResMac is a licensed wholesale independent mortgage bank (IMB) with active production volume. The pilot is designed to validate a repeatable infrastructure layer for mortgage assets. RezyFi is...